Model-based Enterprise Market revenue to reach USD 250 Billion by 2035, says Research Nester
25 juil. 2023 07h00 HE
|
Research Nester
New York, July 25, 2023 (GLOBE NEWSWIRE) -- The global model-based enterprise market size is projected to expand at ~24.17% CAGR between 2023 and 2035. The market is expected to garner a revenue of...
Global Blood Glucose Test Strips Market Report 2022: Steady Shift of Blood Sugar Tests from Diagnostic Laboratories and Hospitals to Easy-To-Use Test Kits Driving Sector
22 sept. 2022 05h53 HE
|
Research and Markets
Dublin, Sept. 22, 2022 (GLOBE NEWSWIRE) -- The "Blood Glucose Test Strips Market By Distribution Type, By Diabetes Type, By End-use, and By Region Forecast to 2030" report has been added to ...
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
07 sept. 2022 02h00 HE
|
Zealand Pharma
Company announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to...
Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association
14 juin 2020 11h00 HE
|
Zealand Pharma
Press release – No. 09 / 2020 Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon rescue therapy at the 80th Scientific Sessions of the American Diabetes Association...
Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia
31 mars 2020 09h45 HE
|
Zealand Pharma
Press Release – No. 04 / 2020 Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal® Rescue Pen for treatment of severe hypoglycemia The...
Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development
08 mars 2018 18h00 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) --
CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel...
Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
15 févr. 2018 17h00 HE
|
Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) --
Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.
08 févr. 2018 18h30 HE
|
Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) --
Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
XOMA Reports Third Quarter 2016 Achievements and Financial Results
09 nov. 2016 09h00 HE
|
XOMA Ltd.
BERKELEY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and...
Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia
03 nov. 2016 11h00 HE
|
The Centre for Drug Research and Development
VANCOUVER, BC and TORONTO, ON--(Marketwired - November 03, 2016) - Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent...